Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,273,604
  • Shares Outstanding, K 129,182
  • Annual Sales, $ 0 K
  • Annual Income, $ -156,730 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.03
Trade IMVT with:

Options Overview Details

View History
  • Implied Volatility 73.71% ( -7.24%)
  • Historical Volatility 55.58%
  • IV Percentile 41%
  • IV Rank 48.08%
  • IV High 138.72% on 03/31/22
  • IV Low 13.50% on 04/01/22
  • Put/Call Vol Ratio 0.80
  • Today's Volume 699
  • Volume Avg (30-Day) 241
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 9,194
  • Open Int (30-Day) 10,632

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate -0.35
  • Low Estimate -0.47
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.32 +23.15%
on 01/11/23
20.24 -12.87%
on 01/09/23
+0.48 (+2.77%)
since 12/27/22
3-Month
10.21 +72.72%
on 10/28/22
20.24 -12.87%
on 01/09/23
+7.23 (+69.40%)
since 10/27/22
52-Week
3.14 +460.73%
on 06/13/22
20.24 -12.87%
on 01/09/23
+10.94 (+163.60%)
since 01/27/22

Most Recent Stories

More News
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.

MRK : 105.56 (-1.23%)
VRTX : 323.20 (+0.68%)
IMVT : 17.75 (+0.85%)
IMCR : 60.40 (-0.45%)
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

MRK : 105.56 (-1.23%)
VRTX : 323.20 (+0.68%)
IMVT : 17.75 (+0.85%)
IMCR : 60.40 (-0.45%)
Are Medical Stocks Lagging Immunovant (IMVT) This Year?

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

IMVT : 17.75 (+0.85%)
MCK : 380.05 (-1.06%)
Are Medical Stocks Lagging BioVie (BIVI) This Year?

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

BIVI : 5.07 (+0.84%)
IMVT : 17.75 (+0.85%)
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

ANGN : 0.6901 (-1.41%)
ASLN : 0.7400 (+1.37%)
IMVT : 17.75 (+0.85%)
IMCR : 60.40 (-0.45%)
Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

ANGN : 0.6901 (-1.41%)
SNDX : 28.25 (-0.28%)
IMVT : 17.75 (+0.85%)
IMCR : 60.40 (-0.45%)
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

BIVI : 5.07 (+0.84%)
IMVT : 17.75 (+0.85%)
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.

AMRN : 1.8250 (+0.83%)
AVIR : 4.60 (+0.66%)
AKRO : 49.28 (+3.42%)
IMVT : 17.75 (+0.85%)
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

ACAD : 18.63 (-0.16%)
AGLE : 0.5007 (+2.18%)
IMVT : 17.75 (+0.85%)
ORIC : 6.13 (+4.79%)
Why Immunovant Stock Is Skyrocketing This Week

The drugmaker announced a $75 million public offering.

IMVT : 17.75 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 19.70
2nd Resistance Point 19.22
1st Resistance Point 18.41
Last Price 17.74
1st Support Level 17.11
2nd Support Level 16.63
3rd Support Level 15.82

See More

52-Week High 20.24
Last Price 17.74
Fibonacci 61.8% 13.71
Fibonacci 50% 11.69
Fibonacci 38.2% 9.68
52-Week Low 3.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar